

Taxotere® + cisplatin: A proven choice for patients ≥ 65 years of age

Treating patients ≥ 65 years of age

- Most patients with NSCLC are older adults¹
- Patients ≥ 65 years of age are underrepresented in many clinical trials and often undertreated in clinical practice¹

Taxotere® + cisplatin: Proven survival in patients ≥ 65 years of age

- Median survival in patients ≥ 65 years of age: Taxotere® + cisplatin 12.6 months vs VC 9.9 months*¹

Ability to remain on therapy

- Taxotere® + cisplatin in patients ≥ 65 years of age: median 5 cycles delivered, with median relative dose intensity 0.93¹
- Similar number of cycles and dose intensity between patients ≥ 65 years of age and younger patients¹
- Fewer patients ≥ 65 years of age discontinued treatment due to adverse events with Taxotere® + cisplatin than with VC (19.5% vs 32.1%)¹

Safety profile in patients ≥ 65 years of age

- Across all study arms, moderately higher incidence of some grade 3/4 toxicities in patients ≥ 65 years of age than in younger patients¹

* These numbers are based on data presented in the clinical reprint and differ from those presented in Taxotere® prescribing information (Taxotere® + cisplatin, 12.1 months [95% CI=9.1–11.8 months]; VC data not reported).²

**Taxotere® + cisplatin: Approved for first-line therapy
for unresectable, locally advanced or metastatic
non-small cell lung cancer (NSCLC)**

Visit www.taxotere.com for full prescribing information.

 **TAXOTERE**®
(docetaxel)
Injection Concentrate


sanofi aventis
Because health matters